(Q38053482)

27 August 2017

title

Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections (English)

1 reference

27 August 2017

1

Lesley J Scott

1 reference

27 August 2017

publication date

1 November 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

72

1 reference

27 August 2017

issue

16

1 reference

27 August 2017

page(s)

2141-2165

1 reference

https://scigraph.springernature.com/pub.10.2165/11209970-000000000-00000

27 August 2017

exact match

0 references

cites work

Management of invasive candidiasis in the intensive care unit

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Epidemiology of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

European expert opinion on the management of invasive candidiasis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Micafungin: a new echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Pharmacokinetics of an elevated dosage of micafungin in premature neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Bronchopulmonary disposition of micafungin in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Distribution of micafungin in the tissue fluids of patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Effects of hepatic CYP3A4 activity on disposition of micafungin in liver transplant recipients with markedly small-for-size grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Early Removal of Central Venous Catheter in Patients with Candidemia Does Not Improve Outcome: Analysis of 842 Patients from 2 Randomized Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Antifungal prophylaxis with micafungin in patients treated for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Candidaemia in Europe: epidemiology and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

Pharmacokinetics of Antifungal Agent Micafungin in Critically Ill Patients Receiving Continuous Hemodialysis Filtration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209970-000000000-00000

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

21 January 2018

1 reference

12 December 2020

Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report

1 reference

12 December 2020

Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections

1 reference

12 December 2020

Safety of micafungin in pediatric clinical trials

1 reference

12 December 2020

Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant

1 reference

12 December 2020

A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation

1 reference

12 December 2020

Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia

1 reference

12 December 2020

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).

1 reference

12 December 2020

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.

1 reference

12 December 2020

Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study

1 reference

12 December 2020

Potential confusion regarding the term 'resistance' in epidemiological surveys

1 reference

12 December 2020

Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei

1 reference

12 December 2020

European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria

1 reference

12 December 2020

Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.

1 reference

12 December 2020

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases.

1 reference

12 December 2020

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS.

1 reference

12 December 2020

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

1 reference

12 December 2020

Safety and pharmacokinetics of repeat-dose micafungin in young infants

1 reference

12 December 2020

10.2165/11209970-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1020231960

0 references

1 reference